Serology for Hepatitis B Virus Inhemodialysis Patients: What is Necessary?
Prabhat Singh, Mohamed Hamdy Yassin* and Maureen Lawlor
University of Pittsburgh Medical Center (UPMC) Mercy, 10550 Ermire Building, 1400 Locust Street, Pittsburgh, PA, 15219, USA
- *Corresponding Author:
- Mohamed H Yassin
University of Pittsburgh Medical Center (UPMC) Mercy
10550 Ermire Building, 1400 Locust Street
Pittsburgh, PA, 15219, USA
Tel: (412) 232-7798
Fax: (412) 232-3292
E-mail: [email protected]
Received date: October 21, 2013; Accepted date: November 13, 2013; Published date: November 17, 2013
Citation: Singh P, Yassin MH, Lawlor M (2013) Serology for Hepatitis B Virus Inhemodialysis Patients: What is Necessary? J Vaccines Vaccin 4:210. doi: 10.4172/2157-7560.1000210
Copyright: © 2013 Singh P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: This was a quality improvement study to evaluate immune status for Hepatitis B virus (HBV) in patients on Hemodialysis (HD) and to improve vaccination rates in these patients. Methods: A prospective quality control study aimed at assuring adequate immunity for HBV in HD patients. Fifty-nine patients on HD were included during two-month study period. The inclusion criteria are all in patients with renal failure requiring HD. The following serologies were checked: HBs Ag, HBs Ab titer, and HBc Ab total. Serum samples were tested using Enzyme linked immunosorbent assay (ELISA) methods. Vaccination was offered to all patients with no evidence of protective Hepatitis B antibody (HBsAb titer) that is titer<10. Results: Out of 59 patients selected in the study, 48 had prior or current vaccination. Among the vaccinated patients, only 29 patients (60.4%) had HBs Ab titers in protective range (titers>10). We also found 6 patients with Hepatitis C virus antibody (HCV Ab) positive. Conclusion: HBV is the leading cause of blood-borne transmission particularly in inpatient HD units. Monitoring HBV serology (HBs Ag, HBs Ab, HBc Ab) on a routine basis is essential to prevent HBV outbreaks within HD units. Monitoring HBs Ag alone is insufficient and should be coupled with additional serology to ensure adequate protection for this particularly vulnerable population. Initiation of early vaccination in patients with DM, chronic kidney disease (CKD), especially in inpatient facilities will ensure better protection.